Interferon-Gamma Primed Human Clonal Mesenchymal Stromal Cell Sheets Exhibit Enhanced Immunosuppressive Function.

Area of Science:

• Regenerative Medicine
• Immunology
• Biotechnology

Background:

• Mesenchymal stromal cells (MSCs) show therapeutic potential for immune diseases via immunomodulatory functions.
• Limitations of MSC therapy include inconsistent function, poor localization, and insufficient retention of suspended cells.
• Current MSC delivery methods impose spatiotemporal dosing constraints, hindering therapeutic efficacy.

Purpose of the Study:

• To develop an improved method for delivering MSCs with enhanced immunosuppressive capabilities.
• To combine in vitro interferon-gamma (IFN-γ) priming with thermoresponsive cultureware for MSC sheet production.
• To evaluate the therapeutic potential of IFN-γ primed MSC sheets for localized inflammatory diseases.

Main Methods:

• Cultured MSCs were primed with IFN-γ in vitro.
• Thermoresponsive cultureware was used to harvest MSCs as scaffold-free cell sheets.
• Expression of immunosuppressive factors (IDO-1, IL-10, PD-L1, PGE2) was analyzed.
• T-cell proliferation inhibition was assessed via direct and indirect cell contact assays.

Main Results:

• IFN-γ primed MSC sheets exhibited dose- and duration-dependent upregulation of immunosuppressive factors (IDO-1, IL-10, PD-L1, PGE2).
• Enhanced inhibition of T-cell proliferation was observed with IFN-γ primed MSC sheets, linked to increased IDO-1 and PGE2.
• The study utilized human clinical-grade bone marrow-derived MSCs, supporting clinical translatability.

Conclusions:

• Combining IFN-γ priming with scaffold-free MSC sheets represents a novel strategy to enhance MSC immunosuppressive potency.
• This approach addresses limitations of traditional MSC therapies, improving cell function, localization, and retention.
• IFN-γ primed MSC sheets show promise for improved treatment of localized inflammatory and immune-related diseases.